Quest Diagnostics Inc., a leading clinical laboratory provider based in Secaucus, New Jersey, has agreed to pay $13,014,576 plus interest to resolve civil allegations under the False Claims Act and the federal Anti-Kickback Statute. Announced on Friday, November 6, 2026, by the U.S. Attorney's Office for the District of New Jersey, the settlement resolves claims that the commercial laboratory provided illegal remuneration in the form of lavish, exclusive entertainment events—specifically premium suite tickets to New York Giants football games—to healthcare providers and executive decision-makers to induce patient laboratory referrals reimbursed by government health programs. Sponsorship Privileges Diverted into Unlawful Referral Inducements Federal prosecutors alleged that the improper conduct spanned a nine-year period from July 25, 2013, through August 3, 2022. In 2013, Quest Diagnostics entered into a multi-year Naming Rights and Sponsorship Agreement with the NFL's New York Giants. The agreement placed Quest's name on the team's headquarters and athletic complex—the Quest Diagnostics Training Center in East Rutherford—and granted the laboratory dedicated hospitality suites at MetLife Stadium for home games, alongside marketing and promotional benefits.
Quest tracked ROI and billed Medicare and Medicaid
Rather than utilizing these corporate hospitality assets for standard promotional activities, federal authorities revealed that Quest systematically deployed these exclusive benefits as commercial inducements. The company targeted healthcare professionals, clinical directors, and healthcare executives from existing and prospective client accounts who held the authority to steer patient laboratory testing business. In multiple instances, complimentary entertainment extended beyond clinical decision-makers to their personal guests and family members.
According to federal filings, the complimentary hospitality offerings encompassed several distinct luxury tiers: Game Day Suite Seats providing luxury MetLife Stadium seating, upscale catering, beverages, parking, and pre-game field access; VIP Training Camp access to view practices alongside player meet-and-greets; Draft Chalk Talks hosted by former Giants alumni legends featuring mock drafts and dinner; and Family Combine Days offering interactive football drills for families. Unsealed records cited specific instances of aggressive targeting, including inviting a major hospital's chief operating officer to exclusive Giants experiences to induce the transfer of an estimated $1.5 million in laboratory business to Quest. Institutional Tracking of Return on Investment and False Claims Submissions Federal investigators determined that Quest's executive management and commercial sales personnel operated the hospitality scheme with rigorous financial calculation. Field sales representatives were mandated to accompany invited healthcare decision-makers to each sporting event. Commercial personnel explicitly tied specific account volume growth benchmarks to the luxury invitations, submitting these sales objectives directly to corporate senior leadership.
Furthermore, across the 2013 through 2016 football seasons, Quest formally tracked its return on investment (ROI) derived from the promotional outings. Corporate tracking systems calculated revenue collected from each client account for up to twelve months following an entertainment event, systematically benchmarking post-event referral revenue against historical pre-event billings. Laboratories then billed Medicare, New York Medicaid, and New Jersey Medicaid for diagnostic testing derived from these unlawfully induced clinical referrals.
Whistleblowers receive $2,472,769 in qui tam award
United States Attorney Robert Frazer emphasized the significance of the enforcement action in an official statement: "This agreement is yet another example of our office's commitment to enforcing the False Claims Act and the Anti-Kickback Statute to protect taxpayer dollars and the Medicare and Medicaid programs from fraud, waste, and abuse. Kickbacks to referring providers, especially by lab companies, corrupt medical judgment, lead to unnecessary lab testing, cause providers to steer patients to labs that offer inducements, and squander taxpayer money." Whistleblowers Secure $2.47 Million Award Under Qui Tam Provisions The investigation originated from a qui tam whistleblower action filed in the U.S. District Court for the District of New Jersey under the caption U.S. ex rel. Rabin, et al v. Quest Diagnostics, Inc. and John Doe Companies 1-10, Civil Action 20-cv-02752. The three relators—Gerard Abate, M.D., Lori Anderson, and Douglas S. Rabin, M.D.—will collectively receive $2,472,769 as their statutory share of the civil recovery under False Claims Act provisions.
In conjunction with the monetary settlement, Quest executed a five-year Corporate Integrity Agreement with the Office of Inspector General at the U.S. Department of Health and Human Services (HHS-OIG). The compliance pact mandates that an independent review organization evaluate the laboratory's operational risk assessments and compliance audits relating to remuneration exchanged with referral sources.
Naomi D. Gruchacz, Special Agent in Charge of HHS-OIG, affirmed that violations of the Anti-Kickback Statute compromise medical judgment and threaten the integrity of federal healthcare programs. FBI Newark Special Agent in Charge Stefanie Roddy stated that the FBI is committed to rooting out healthcare fraud in New Jersey and beyond, emphasizing that Americans must be able to trust their healthcare system. Federal authorities reiterated that the claims resolved by the settlement agreement remain allegations only, with no legal determination or admission of corporate liability.
